Glasdegib

The Basics

What is Glasdegib?

Used along with cytarabine as a first treatment for acute myeloid leukemia.

Brand names for Glasdegib

N/A

How Glasdegib is classified

Antineoplastic Agents, Enzyme Inhibitors, Protein Kinase Inhibitors, Signal Transduction Inhibitors

Glasdegib During Pregnancy

Glasdegib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Glasdegib while pregnant

N/A

Taking Glasdegib While Breastfeeding

What are recommendations for lactation if you're taking Glasdegib?

No information is available on glasdegib during breastfeeding. It is 91% bound to plasma proteins, so amounts in milk are likely to be low. With a half-life of 17.4 hours, it is likely to be eliminated from milk by 4 to 7 days after the last dose. However, the manufacturer recommends that breastfeeding be discontinued during glasdegib therapy and for at least 30 days after the last dose.

Maternal / infant drug levels

No information is available on glasdegib during breastfeeding. It is 91% bound to plasma proteins, so amounts in milk are likely to be low. With a half-life of 17.4 hours, it is likely to be eliminated from milk by 4 to 7 days after the last dose. However, the manufacturer recommends that breastfeeding be discontinued during glasdegib therapy and for at least 30 days after the last dose.

Possible effects of Glasdegib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Glasdegib

None listed